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Abstract
Background: Previous studies suggested that genetic polymorphisms in the epidermal growth
factor receptor (EGFR) gene had been implicated in the susceptibility to some tumors and
inflammatory diseases. EGFR has been recently implicated in vascular pathophysiological processes
associated with excessive remodeling and atherosclerosis. Acute coronary syndrome (ACS) is a
clinical manifestation of preceding atherosclerosis. Our purpose was to investigate the association
of the EGFR polymorphism with the risk of ACS. In this context, we analyzed the HER-1 R497K
and EGFR intron 1 (CA)n repeat polymorphisms in 191 patients with ACS and 210 age- and sex-
matched controls in a Chinese population, using a polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) strategy and direct sequencing.
Results: There were significant differences in the genotype and allele distribution of R497K
polymorphism of the EGFR gene between cases and controls. The Lys allele had a significantly
increased risk of ACS compared with the Arg allele (adjusted OR = 1.49, 95% CI: 1.12–1.98,
adjusted P = 0.006). However, no significant relationship between the number of (CA)n repeats of
EGFR intron 1 (both alleles < 20 or any allele ≥ 20) and the risk of ACS was observed (adjusted
OR = 0.97, 95% CI: 0.58–1.64, adjusted P  = 0.911). Considering these two polymorphisms
together, there was no statistically significant difference between the two groups.
Conclusion: R497K polymorphism of the EGFR gene is significantly associated with the risk of
ACS. Our data suggests that R497K polymorphism may be used as a genetic susceptibility marker
of the ACS.
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Background
Acute coronary syndrome (ACS) is a clinical manifesta-
tion of preceding atherosclerosis, inflammation and
thrombosis [1]. It constitutes an important cause of mor-
tality and morbidity in many countries including China.
Although the exact mechanism of ACS pathogenesis is not
fully known, many factors such as age, gender, smoking,
hypertension, diabetes mellitus, hypercholesterolemia,
obesity and sedentary lifestyle are involved in the disease
[2-4]. In addition, several studies have shown that genetic
factors such as single nucleotide polymorphisms (SNPs)
of angiotensin converting enzyme (ACE), platelet glyco-
protein IIb HPA-3, and matrix metalloproteinase-3
(MMP-3) also play a crucial role in the development of
ACS [5-7]. Despite many gene SNPs [5-14] have been
reported to be associated with ACS, it is necessary to dis-
cover novel gene variants in the risk of ACS. Firstly, ACS is
a disease related to multiple genes. Secondly, the molecu-
lar mechanism of ACS is unclear, and it may be benefit to
elucidate the pathogenesis of ACS by finding novel gene
variants.
The epidermal growth factor receptor (EGFR) is a trans-
membrane glycoprotein of 170 kDa (1186 amino acids)
encoded by a gene located in the short arm of chromo-
some 7 (chromosome 7p12.1–12.3) [15]. And it contains
26 exons [16]. A polymorphic variant of the EGFR arising
from a single nucleotide change (G → A) leading to an
arginine (Arg) →Lysine (Lys) substitution in codon 497
(HER-1 R497K) in the extracellular domain within sub-
domain IV of the EGFR gene has been identified [17]. It is
one of the key polymorphisms within the EGFR signaling
pathway. An in vitro study has shown that the variant
HER-1 497K has attenuated functions in ligand binding,
growth stimulation, tyrosine kinase activation, and induc-
tion of protooncogenes myc, fos, and jun compared with
the "wild-type" HER-1 497R [18]. Another polymorphic
variant of the EGFR is a highly polymorphic region in
intron 1 of the EGFR gene which is associated with tran-
scription levels of EGFR in vitro and in vivo [19,20]. The
length of this (CA)n dinucleotide polymorphism corre-
lates inversely with the transcriptional activity of the gene.
In vitro studies have shown that the transcriptional activity
in cell lines containing a prolonged polymorphic region
(>20 CA repeats) was markedly reduced compared with
cells containing a shorter allele (16 repeats). Recently, sev-
eral studies reported that genetic polymorphisms of the
EGFR gene had been implicated in the risk of a range of
tumors [21-26]. In addition to its prominent role in the
development of several cancers [27], EGFR has been cur-
rently implicated in vascular pathophysiological proc-
esses associated with excessive remodeling and
atherosclerosis [28,29]. Moreover, EGFR has been identi-
fied on intimal smooth muscle cells within human
atherosclerotic plaque and cultured rat aortic smooth
muscle cells, which mediates cell proliferation and DNA
synthesis [30-32]. Atherosclerosis, regarded as a chronic
inflammatory process [33], plays a fundamental role in
the pathogenesis of ACS.
Therefore, we hypothesized that HER-1 R497K and EGFR
intron 1 (CA)n repeat polymorphisms may modulate the
susceptibility to ACS. To test this hypothesis, we con-
ducted a hospital-based case-control study to evaluate the
potential association between HER-1 R497K and intron 1
(CA)n repeat polymorphisms in the EGFR gene and the
risk of ACS in a Chinese population.
Results
Characteristics of the study population
The demographics of the cases and controls enrolled in
this study are shown in Table 1. There were no significant
differences between the cases and controls for the age,
gender distribution and body mass index. However, the
smoking status, total cholesterol, LDL-cholesterol and
triglycerides were significantly higher in the ACS group
than in the control group(P < 0.001), whereas HDL-cho-
lesterol was significantly lower in the ACS group than in
the control group(P  < 0.001). Hypertension, diabetes
mellitus and coronary stenosis were observed only in
patients with ACS.
HER-1 R497K polymorphism
The genotype and allele frequencies of the HER-1 R497K
polymorphism between the controls and the cases are
shown in Table 2. And the genotype distributions were in
Hardy-Weinberg's equilibrium. There were significant dif-
ferences in the genotype and allele frequency of the HER-
1 R497K polymorphism between ACS and control groups.
Compared with the Arg allele, the frequency of the Lys
allele was significantly higher in the patient group than in
the control group (adjusted OR = 1.49, 95% CI: 1.12–
1.98, adjusted P = 0.006).
EGFR intron 1 (CA)n repeat polymorphism
In 420 chromosomes from 210 controls, 10 alleles with
14–23 CA repeats were found (Table 3). The allele distri-
bution in healthy Chinese individuals, ranging from 0.5%
to 42.9% with a predominance of 16 and 20 repeats, was
in agreement with that of Asian populations reported in a
previous study [34]. The allele distribution in ACS
patients was similar to the control group except that a
novel (CA)n repeat length of n = 13 was determined in one
patient. No significant difference was observed in the dis-
tribution of genotype and allele between cases and con-
trols.
To evaluate the effect of the number of (CA)n repeats on
patients with ACS and controls, we separated the geno-
types into two subgroups: both (CA)n repeats < 20 andBMC Medical Genetics 2008, 9:74 http://www.biomedcentral.com/1471-2350/9/74
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any (CA)n  repeats  ≥ 20. No significant relationship
between the number of (CA)n repeats of EGFR intron 1
and the risk of ACS was observed (adjusted OR = 0.97,
95% CI: 0.58–1.64, adjusted P = 0.911) (Table 2).
Combined analysis and linkage disequilibrium
When we considered these two polymorphisms together,
there was no statistically significant difference between
patients with ACS and controls (data not shown).
No statistically significant evidence for linkage disequilib-
rium between the HER-1 R497K polymorphism and EGFR
(CA)n repeat polymorphism was found in our study (data
not shown).
Stratified analysis
When the analyses were stratified by hypertension and
diabetes mellitus, no significant association was observed
between the R497K polymorphism and the risk of ACS
(data not shown).
Multivariable logistic regression analysis
This analysis showed that independent risk factors for
ACS were cigarette smoking, total cholesterol, LDL-cho-
lesterol, triglycerides, and R497K (Table 4).
Discussion
In this retrospective, hospital-based case-control study, we
found that the frequency of Lys allele in the ACS group
was significantly higher than that in control. Additionally,
multivariable logistic regression analysis showed that
Table 1: The characteristics of the study population
Control ACS Pa
n = 210 (%) n = 191 (%)
Sex (M/F) 132/78 (62.9/37.1) 112/79 (58.6/41.4) NS
Age (years; mean ± SD) 59.4 ± 11.2 60.6 ± 10.9 NS
Body mass index (kg/m2; mean ± SD) 25.2 ± 3.3 26.6 ± 4.2 NS
UA/NSTEMI/STEMI 102/49/40(53.4/25.7/20.9)
Smoking status 
(never/former/current)
111/53/46 
(52.9/25.2/21.9)
62/73/56 
(32.5/38.2/29.3)
< 0.001
Total cholesterol (mmol/l; mean ± SD) 3.57 ± 0.93 5.24 ± 1.19 < 0.001
HDL-cholesterol (mmol/l;mean ± SD) 1.15 ± 0.40 1.02 ± 0.42 < 0.001
LDL-cholesterol (mmol/l; mean ± SD) 2.21 ± 0.69 3.04 ± 0.99 < 0.001
Triglycerides (mmol/l; mean ± SD) 1.27 ± 0.55 1.92 ± 0.90 < 0.001
Hypertension 85 (44.5)
Diabetes mellitus 38 (19.9)
Number of stenosis vessels
1 88 (46.1)
2 75 (39.3)
3 28 (14.7)
ACS, acute coronary syndrome; UA, unstable angina; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation 
myocardial infarction; NS, not significant
a ACS vs. controls by Student's t-test or Chi-squared test.
Table 2: The genotype and allele distribution of EGFR polymorphisms in ACS patients and controls
Polymorphism Control 
n = 210 (%)
ACS 
n = 191 (%)
Crude OR 
(95% CI)
Adjusted ORa 
(95% CI)
Adjusted 
Pa
R497K
genotypes
Arg/Arg 45 (21.4) 32 (16.8) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Arg/Lys 107 (51.0) 79 (41.4) 1.04 (0.61–1.78) 1.07 (0.62–1.85) 0.807
Lys/Lys 58 (27.6) 80 (41.9) 1.94 (1.10–3.41) 1.98 (1.12–3.49) 0.018
alleles
Arg allele frequency 197 (46.9) 143 (37.4) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Lys allele frequency 223 (53.1) 239 (62.6) 1.48 (1.11–1.96) 1.49 (1.12–1.98) 0.006
(CA)n repeats
Both (CA)n repeats < 20 35 (16.7) 33 (17.3) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Any (CA)n repeats ≥ 20 175 (83.3) 158 (82.7) 0.96 (0.57–1.61) 0.97 (0.58–1.64) 0.911
a adjusted for sex and age by the logistic regression model.BMC Medical Genetics 2008, 9:74 http://www.biomedcentral.com/1471-2350/9/74
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R497K was an independent risk factor for ACS besides
some classical risk factors, such as smoking status, total
cholesterol, LDL-cholesterol, and triglycerides. It indicates
that Lys allele may be a risk factor for ACS in a Chinese
population. This finding is in consistent with our hypoth-
esis and suggests that the R497K polymorphism may be
used as a genetic susceptibility marker of the ACS.
For the (CA)n repeat in intron 1 of EGFR polymorphism,
alleles 20 (42.9%) and 16 (15.7%) were the two most
common in a Chinese population in our current study,
which was similar to that reported by Liu et al. [34] in a
U.S. Asian population (62.9% for allele 20 and 17.4% for
allele 16). However, the allelic distribution was reversed
in Caucasians and African-Americans, with allele 16 the
most common (43.2% and 41.7%, respectively), followed
by allele 20 at a much lower frequency (21.0% and
14.3%, respectively). It suggests that the allelic frequen-
cies of the EGFR intron 1 polymorphism might vary
among different ethnic groups.
The EGFR, also known as HER-1 or erbB-1, is a member of
the human epithelial receptor tyrosine kinase family. The
EGFR gene is located on chromosome 7 [15] and contains
26 exons [16]. Exons 1 to 14 code for the extracellular
domain. Exon 15 codes for the transmembrane domain,
and exons 16 to 26 code for the intracellular domain [35].
Transcription of the EGFR gene is regulated by two
enhancer elements. The first is located upstream near the
transcription initiation site and the second downstream in
intron 1 [36]. The latter contains a characteristic simple
sequence repeat (SSR) of CA dinucleotides, the length of
which exhibits interethnic differences [34]. In addition,
the length of this polymorphism has been observed to
correlate inversely with EGFR transcription in both in vitro
experiments and breast cancer specimens. The longer
allele with 21 repeats was shown an 80% reduction of
gene expression compared with the shorter allele with 16
repeats [19,20]. In this present study, no significant differ-
ence was observed in EGFR intron 1 (CA)n repeat poly-
morphism between cases and controls. When taking HER-
1 R497K and EGFR intron 1 (CA)n repeat polymorphisms
into together, there was no statistically significant differ-
ence between patients with ACS and controls as well.
Currently, EGFR is considered as a convergence point in
the complex signaling network and regulation of cellular
functions, such as cell growth, differentiation, motility,
survival and death [37-39]. Thereby, it plays a crucial role
in various pathophysiological processes, including
atherosclerosis. EGFR has been demonstrated on both
intimal smooth muscle cells within human atheroscle-
rotic plaque and cultured rat aortic smooth muscle cells
[30-32]. Furthermore, it has previously reported that
EGFR is present on rabbit peripheral blood leucocytes,
and co-localises with macrophages within lesions of
atherosclerosis in the cholesterol-fed rabbit [40], which
mediates both chemotactic responses towards monocytes
and mitogenic responses towards monocyte-derived mac-
rophages in vitro. Transactivation of the EGFR mediates
endothelin-1 (a powerful vasoconstrictor, involving in
vasospastic diseases such as coronary artery disease) sign-
aling in vascular smooth muscle cells and isolated arteries
[41]. This identification heightens the potential impor-
tance of EGFR in atherogenesis and other inflammatory
disease. A few studies have shown that polymorphism of
EGFR was associated with susceptibility of some inflam-
matory diseases [42,43]. For example, Wang et al. [42]
reported that asthmatic patients had a significantly higher
incidence of having shorter alleles (≤ 16 CA repeats) com-
pared with control subjects (P < 0.05). Martin et al. [43]
reported that the frequency of the WT (Arg) allele at posi-
tion R497K in the EGFR gene was significantly higher in
ulcerative colitis than in controls (P = 0.04).
However, no previous study has shown the relationship
between HER-1 R497K and EGFR intron 1 (CA)n repeat
polymorphisms and patients with ACS. To our knowl-
edge, the present pilot study is the first to investigate the
association between them. We found that R497K but not
Table 3: The allele distribution of EGFR intron 1 (CA)n repeat in 
ACS patients and controls
Control (n = 210) ACS (n = 191)
n% a n% a
13 0 0.0 1 0.3
14 2 0.5 3 0.8
15 23 5.5 16 4.2
16 66 15.7 69 18.1
17 28 6.7 24 6.3
18 13 3.1 5 1.3
19 55 13.1 39 10.2
20 180 42.9 172 45.0
21 38 9.0 31 8.1
22 12 2.9 21 5.5
23 3 0.7 1 0.3
aDoes not add up to 100.0% because of rounding.
Table 4: Results of multivariable logistic regression analysis: final 
significant variables in equation
Variable Odds ratio 95% CI P
Smoker 2.63 1.23–5.63 0.013
Total cholesterol 7.29 4.60–11.56 < 0.001
LDL-cholesterol 13.75 6.77–27.93 < 0.001
Triglycerides 6.40 3.46–11.86 < 0.001
R497K 1.72 1.03–2.86 0.039BMC Medical Genetics 2008, 9:74 http://www.biomedcentral.com/1471-2350/9/74
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(CA)n repeat polymorphism might be used as a genetic
susceptibility marker of the ACS. The exact mechanism by
which the Lys allele may be associated with the risk of ACS
is unclear. In 1993, a variant EGFR of an arginine to lysine
substitution at codon 497 was identified [17]. Wild-type
EGFR (Arg allele) differs from mutant EGFR (Lys allele)
with respect to epithelial proliferation following the
administration of EGF and TGF-α in rodents [18]. Thus, it
is possible that mutations which influence the function or
expression of EGFR (such as attenuating its ligand binding
as well as subsequent activation of its downstream effec-
tors) might predispose to the development of ACS.
Conclusion
To conclude, in the present retrospective study, we found
that HER-1 R497K polymorphism was significantly asso-
ciated with the risk of ACS in a Chinese population. These
results suggested that genetic polymorphism of EGFR
(arginine →Lysine mutation) might be clinically impor-
tant in the development and progression of ACS. Never-
theless, there are some limitations in our study, and
several questions still should be addressed. For instance,
the molecular mechanism by which the EGFR gene poly-
morphisms are associated with ACS is unknown. It should
also be emphasized that other polymorphisms in linkage
disequilibrium with the R497K and (CA)n repeat may also
contribute to variability in EGFR expression. In addition,
the inadequate study design such as non-random sam-
pling and a limited sample size should also be considered.
Therefore, One needs to explore further, whether EGFR
polymorphisms are an independent risk factor or an indi-
rect marker of different genetic and environmental factors.
Further studies are required to evaluate haplotype, rela-
tionship among genotypes, and the molecular mecha-
nisms by which EGFR is involved in susceptibility to ACS
in diverse ethnic populations and larger number of
patients.
Methods
Study population
The case-control population consisted of 401 adult unre-
lated Chinese who were selected from the same popula-
tion living in China (Table 1). A total of 191 ACS patients
(112 males and 79 females, mean age: 60.6 ± 10.9),
including 102 of whom suffering from unstable angina
(UA), 49 from non-ST-segment elevation myocardial inf-
arction (NSTEMI) and 40 from ST-segment elevation
myocardial infarction (STEMI), were recruited from West
China hospital, Sichuan University between July 2005
and January 2007. The diagnosis of ACS was performed
according to the definitions proposed by the European
Society of Cardiology and the American College of Cardi-
ology [44]. Exclusion criteria were evidence of significant
concomitant diseases, in particular, hemodynamic valvu-
lar heart disease, known cardiomyopathy and malignant
diseases, as well as a febrile condition.
The control group included 210 healthy volunteers (132
males and 78 females, mean age: 59.4 ± 11.2) who visited
the general health check-up division at West China Hospi-
tal, Sichuan University. Selection criteria for controls were
no history of heart disease or systemic disease and found
to be normal by physical examination, electrocardiogram,
and echocardiogram. There was no significant difference
between patients and control subjects in terms of gender
and age distribution. Written informed consent was
obtained from all the subjects, and the study was per-
formed with the approval of the ethics committee of Chi-
nese Human Genome.
Plasma lipid determination
The method was described in our previous study [45]. In
brief, venous blood sample was drawn after an overnight
fast. Serum cholesterol, HDL-cholesterol, LDL-cholesterol
and triglycerides were measured by automated enzymatic
methods. All blood lipid samples were examined at
Olympus-1000 automated analyzer (Japan).
DNA extraction and EGFR genotyping
Genomic DNA was extracted from peripheral blood with
an extraction kit (Bioteke Corporation; Beijing, China)
according to the manufacturer's instructions. R497K in
exon 13 genotype was determined by using a PCR-RFLP
assay and DNA sequencing analysis. The PCR primers
were 5'-TGCTGTGACCCACTCTGTCT-3' (forward) and 5'-
CCAGAAGGTTGCACTTGTCC-3' (reverse). The PCR reac-
tions were performed in a total volume of 25 μl contain-
ing 100 ng genomic DNA, 20 pM of each primer, 0.2 mM
dNTPs, 20 mM Tris-HCl (pH 8.8), 10 mM KCl, 10 Mm
(NH4)2SO4, 2 mM MgSO4, 0.1% Triton X-100, and 1 unit
of Taq polymerase (New England BioLabs). The PCR cycle
conditions consisted of an initial denaturation step at
94°C for 5 min followed by 34 cycles of 30 s at 94°C; 45
s at 60°C and 45 s at 72°C; and a final elongation at 72°C
for 10 min. After PCR amplification, the PCR products
were digested at 37°C overnight with the restriction
enzyme Mva I (Fermentas). The digested PCR products,
including a single fragment of 155 bp (uncuttable by
restriction enzyme) and two fragments of 88 bp and 67 bp
(cuttable), were resolved on 2% agarose gel and 8% acry-
lamide gel respectively, and stained with ethidium bro-
mide for visualization under UV light.
The (CA)n repeat polymorphism in intron 1 of the EGFR
gene was genotyped by direct-sequencing. The primers
were 5'-TTCTCCTCAAAACCCGGAGAC-3' (forward) and
5'-GTCACGAAGCCAGACTCGCT-3' (reverse). PCR condi-
tions were as follows: initial denaturation at 94°C for 5
min; 30 cycles of denaturation at 94°C for 30 s, annealingBMC Medical Genetics 2008, 9:74 http://www.biomedcentral.com/1471-2350/9/74
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at 60°C for 30 s, extension at 72°C for 30 s, and final
extension of 72°C for 10 min. After PCR amplification,
the exact number of the (CA)n repeat was confirmed by
direct sequencing.
Statistical analysis
In this exploratory, retrospective study, genotype, allele
frequencies and stratified analysis of EGFR were com-
pared between ACS cases and controls using the χ2 test
and Fisher's exact test when appropriate. The association
between R497K polymorphism and risk of ACS was esti-
mated by computing the ORs and their 95% CIs using
logistic regression analyses for crude ORs, adjusted ORs
and adjusted P  value when adjusted for sex and age.
Demographic and clinical data between groups were com-
pared by χ2 test or Student's t-test. Hardy-Weinberg equi-
librium was tested for with a goodness of fit χ2-test with
one degree of freedom to compare the observed genotype
frequencies among the subjects with the expected geno-
type frequencies. Multivariable logistic regression analysis
was performed on the effect of the EGFR polymorphism
and other risk factors for ACS. Statistical significance was
assumed at the P < 0.05 level. The SPSS statistical software
package version 11.5 was used for all of the statistical
analysis.
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